Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 12/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267288 | 0.90 | BRD4 (0.60) | AXLBRD4EGFR | |
| SCHEMBL271484 | 0.84 | BRD4 (0.52) | AXLBRD4AURKASYKJAK3 | |
| SCHEMBL14390102 | 0.84 | BRD4 (0.48) | AXLBRD4AURKAJAK3 | |
| SCHEMBL13072390 | 0.83 | BRD4 (0.48) | AXLBRD4AURKASYKEGFR | |
| SCHEMBL271184 | 0.82 | BRD4 (0.48) | AXLBRD4AURKASTK17ASYK | |
| SCHEMBL264398 | 0.80 | BRD4 (0.63) | AXLBRD4AURKASTK17ASYK | |
| SCHEMBL270946 | 0.79 | AXL (0.80) | AXLBRD4JAK3AURKB | |
| SCHEMBL10260237 | 0.76 | BCL6 (0.55) | AXLBRD4AURKASTK17ASYK | |
| SCHEMBL17915930 | 0.74 | AURKA (0.51) | AXLBRD4AURKASTK17ASYK | |
| SCHEMBL270357 | 0.74 | BRD4 (0.67) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | AXL 267/4885BRD4 142/4885AURKA 75/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | AXL 2199/4885BRD4 1036/4885AURKA 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.